Abstract
Gastrointestinal (GI) tract cancers account for a significant proportion of human malignancies. While classical multistep carcinogenesis is characterized by the stochastic accumulation of genetic mutations, additional extrinsic factors can also contribute to tumor promotion. Inflammation plays a critical role in cancers of the GI tract, for which the two major etiological factors are tissue injuries and altered microbiota. Together with infiltrating immune cells, all of these components generate a dynamic tumor microenvironment that inevitably induces malignant progression and metastatic growth. Crosstalk between tumor and immune cells is mediated by a multitude of pro- and anti- inflammatory cytokines. Their biological actions are propagated in both tumor and immune cells through an intricate network of intracellular signaling pathways that ultimately modulate essential cellular functions such as tumorigenic properties and lineage specification. Using the vast amount of information stored in the database on genetic changes associated with human cancers that has been collected over the past decades, this book chapter will first profile the genomic and transcriptomic landscapes of some of the major GI tract cancers. Critical driver genes and pro-inflammatory cytokines will be discussed in detail. The mechanisms by which genetic mutations in cancer cells can provoke inflammation and vice versa will be explored. The way in which the symbiotic relationship between cancer cells and chronic inflammation can modulate tumor cell behavior will be examined. We will present some of the most recent advancements in the targeting of inflammation for the treatment of GI tract cancers.
Keywords: Cancer, colorectal cancer, esophageal cancer, gastric cancer, hepatocellular carcinoma, inflammation, oncogenes, pancreatic ductal adenocarcinoma, tumor suppressors.
Current Pharmaceutical Design
Title:The Genetic Landscapes of Inflammation-Driven Gastrointestinal Tract Cancers
Volume: 21 Issue: 21
Author(s): Yubing Wang, Mingfei Yan, Penelope Mei-Yu Or and Andrew Man-Lok Chan
Affiliation:
Keywords: Cancer, colorectal cancer, esophageal cancer, gastric cancer, hepatocellular carcinoma, inflammation, oncogenes, pancreatic ductal adenocarcinoma, tumor suppressors.
Abstract: Gastrointestinal (GI) tract cancers account for a significant proportion of human malignancies. While classical multistep carcinogenesis is characterized by the stochastic accumulation of genetic mutations, additional extrinsic factors can also contribute to tumor promotion. Inflammation plays a critical role in cancers of the GI tract, for which the two major etiological factors are tissue injuries and altered microbiota. Together with infiltrating immune cells, all of these components generate a dynamic tumor microenvironment that inevitably induces malignant progression and metastatic growth. Crosstalk between tumor and immune cells is mediated by a multitude of pro- and anti- inflammatory cytokines. Their biological actions are propagated in both tumor and immune cells through an intricate network of intracellular signaling pathways that ultimately modulate essential cellular functions such as tumorigenic properties and lineage specification. Using the vast amount of information stored in the database on genetic changes associated with human cancers that has been collected over the past decades, this book chapter will first profile the genomic and transcriptomic landscapes of some of the major GI tract cancers. Critical driver genes and pro-inflammatory cytokines will be discussed in detail. The mechanisms by which genetic mutations in cancer cells can provoke inflammation and vice versa will be explored. The way in which the symbiotic relationship between cancer cells and chronic inflammation can modulate tumor cell behavior will be examined. We will present some of the most recent advancements in the targeting of inflammation for the treatment of GI tract cancers.
Export Options
About this article
Cite this article as:
Wang Yubing, Yan Mingfei, Or Mei-Yu Penelope and Chan Man-Lok Andrew, The Genetic Landscapes of Inflammation-Driven Gastrointestinal Tract Cancers, Current Pharmaceutical Design 2015; 21 (21) . https://dx.doi.org/10.2174/1381612821666150514103332
DOI https://dx.doi.org/10.2174/1381612821666150514103332 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Spinal Microvascular Expression of PV-1 is Associated with Inflammation, Perivascular Astrocyte Loss, and Diminished EC Glucose Transport Potential in Acute SCI
Current Neurovascular Research Application of 3D Biomimetic Models in Drug Delivery and Regenerative Medicine
Current Pharmaceutical Design Identification of Small Molecule Sulfonic Acids as Ecto-5'-Nucleotidase Inhibitors
Medicinal Chemistry Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology Artificial Virus as Trump-card to Resolve Exigencies in Targeted Gene Delivery
Mini-Reviews in Medicinal Chemistry Antibody-Targeted Immunoliposomes for Cancer Treatment
Mini-Reviews in Medicinal Chemistry Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Radioprotective Gene Therapy
Current Gene Therapy The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Current Status and Future Perspectives of Chemoprevention in Head and Neck Cancer
Current Cancer Drug Targets A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging
Current Pharmaceutical Design Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Intracellular Trafficking Mechanism and Cytosolic Protein Interactions of a Non Viral Gene Delivery Vector: Studies Based on Transferrin Conjugated Pullulan-PEI
Current Nanoscience Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews Oleamide Derivatives are Prototypical Anti-Metastasis Drugs that Act by Inhibiting Connexin 26
Current Drug Safety